Core Viewpoint - The company, Beijing Baipusais Biotechnology Co., Ltd., is actively expanding its product offerings in the fields of CAR-T cell therapy, recombinant proteins, and monkeypox-related products, while benefiting from the depreciation of the RMB and being recognized as a "specialized, refined, distinctive, and innovative" enterprise [2][3][4]. Group 1: Company Performance - The company reported a revenue of 613 million yuan for the period from January to September 2025, representing a year-on-year growth of 32.26% [9]. - The net profit attributable to the parent company for the same period was 132 million yuan, showing a year-on-year increase of 58.61% [9]. - The company has distributed a total of 432 million yuan in dividends since its A-share listing, with 312 million yuan distributed over the past three years [10]. Group 2: Product Development - The company has launched a specific antibody targeting the CD19 antigen in CAR-T cell therapy, enhancing detection methods and expanding its product line related to cell and gene therapy [2]. - It has developed high-quality recombinant proteins for various disease targets and biomarkers, supporting the research and production needs of biopharmaceuticals [2]. - The company is actively developing products related to monkeypox, including recombinant proteins, antibodies, and test kits, to aid in vaccine and therapeutic drug development [2]. Group 3: Market Position and Recognition - The company has been recognized as a national-level "specialized, refined, distinctive, and innovative" small giant enterprise, which signifies its strong market position and innovation capabilities [3]. - As of the 2024 annual report, overseas revenue accounted for 66.46% of total revenue, benefiting from the depreciation of the RMB [4]. - The company operates in the pharmaceutical and biotechnology sector, specifically in the bioproducts category, and is involved in various concept sectors including financing, specialized innovation, and artificial intelligence [9].
百普赛斯跌1.39%，成交额7926.34万元，今日主力净流入-721.75万